A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
Status:
Withdrawn
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
- Evaluate the safety and tolerability of multiple doses of MEDI-538 by continuous IV
infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for curative
therapy.
- Determine the maximum tolerated dose of MEDI-538 administered by continuous IV infusion.